-

Bayer’s XtendFlex Soybeans Gain Final Key Regulatory Approval

European Commission’s Green Light Enables a Full Launch in 2021

ST. LOUIS--(BUSINESS WIRE)--Bayer announced today that the European Commission has authorized XtendFlex soybean technology for food, feed, import and processing in the European Union. This milestone represents the final key authorization for XtendFlex soybeans. With this approval in hand, Bayer can now look forward to a full launch in the United States and Canada in 2021 and expects to be in a strong position to supply 20 million U.S. soy acres when the selling season arrives.

“XtendFlex soybeans will be Bayer’s second major product launch in soybeans in the last 5 years,” said Lisa Safarian, President of Crop Science North America. “The upcoming launch in 2021 highlights the strength of the Bayer soybean pipeline, as well as the investment that Bayer continues to make in our soybean portfolio and the Roundup Ready Xtend Crop System. XtendFlex soybeans are the latest example of Bayer developing innovative products to help farmers meet challenges on their farm.”

XtendFlex soybeans, Bayer’s newest soybean technology, are built upon the high-yielding Roundup Ready 2 Xtend soybean technology that growers have grown to trust with the additional tolerance to glufosinate herbicides. XtendFlex soybeans provide growers with additional flexibility to manage tough-to-control and resistant weeds.

“We’ve seen great demand for XtendFlex soybeans from our customers,” said Lisa Streck, Bayer soybean launch lead. “Based on that demand, we’ve developed a supply plan to meet the market demand in 2021, across all maturities, Bayer brands and licensees. We expect the launch of XtendFlex to match the launch scale of Roundup Ready 2 Xtend soybeans, which were planted on 20 million acres in their first year of commercial availability. This technology offers outstanding yield potential and weed control flexibility that will benefit soybean farmers across the U.S.”

To learn more about XtendFlex soybeans, please visit RoundupReadyXtend.com.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to www.bayer.com.

Contacts

Bayer - Brian Leake 314.370.3285
brian.leake@Bayer.com

Bayer


Release Versions

Contacts

Bayer - Brian Leake 314.370.3285
brian.leake@Bayer.com

More News From Bayer

ASCO 2026: Bayer to Present New Data Across Oncology Portfolio

WHIPPANY, N.J.--(BUSINESS WIRE)--ASCO 2026: Bayer to Present New Data Across Oncology Portfolio...

Bayer’s KERENDIA® (finerenone) Granted Priority Review of Supplemental New Drug Application by U.S. FDA for Treatment of Adults with Type 1 Diabetes and Chronic Kidney Disease

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer announced today that the U.S. Food and Drug Administration (FDA) accepted its supplemental New Drug Application (sNDA) and granted Priority Review designation for KERENDIA® (finerenone), which is being investigated for the treatment of adults with type 1 diabetes (T1D) and chronic kidney disease (CKD). Key Facts The sNDA was supported by the Phase III FINE-ONE trial, which showed KERENDIA significantly reduced urine albumin-to-creatinine rati...

Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer: WHAT’S HAPPENING Bayer today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) and granted Priority Review designation for its investigational oral Factor XIa (FXIa) inhibitor, asundexian, for the prevention of secondary stroke in patients following a non-cardioembolic ischemic stroke or transient ischemic attack (TIA). The NDA is based on positive results from the global, pivotal Phase III OC...
Back to Newsroom